ADIPOQ and rheumatoid arthritis: Baricitinib, a JAK inhibitor blocking central inflammatory signaling pathways, was recently shown to decrease systemic inflammation biomarkers, such as IL-6, CRP, as well as adiponectin, in rheumatoid arthritis patients [53].